On July 18, 2024, Dr Reddy’s Laboratories Ltd announced a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited. This agreement allows Dr Reddy’s to market Vonoprazan tablets in India. Vonoprazan is a new, orally active medication that blocks stomach acid and is used to treat conditions like reflux esophagitis and other acid-peptic disorders. Dr …